Kampanjeplan Adynxx Inc
Avansert tidsplan
Enkel graf
Om selskapet Adynxx Inc
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.ISIN | US00784D1037 |
---|---|
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.adynxx.com |
Цена ао | 0.0001 |
Prisendring per dag: | 0% (0.0001) |
---|---|
Prisendring per uke: | 0% (0.0001) |
Prisendring per måned: | 0% (0.0001) |
Prisendring over 3 måneder: | 0% (0.0001) |
Prisendring over seks måneder: | 0% (0.0001) |
Prisendring per år: | 0% (0.0001) |
Prisendring over 3 år: | -99.76% (0.0411) |
Prisendring over 5 år: | -100% (2.48) |
Prisendring over 10 år: | 0% (0.0001) |
Prisendring siden begynnelsen av året: | 0% (0.0001) |
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
Veileder | Stillingstittel | Betaling | Fødselsår |
---|---|---|---|
Mr. Richard Orr Esq., J.D. | President, CEO, Principal Financial Officer & Director | 1961 (64 år) | |
Dr. Julien Mamet Ph.D. | Founder, Chief Scientific Officer & Director | 1976 (49 år) | |
Mr. William Martin | Executive Vice President of Corporate Development & Operations | ||
Ms. Dina Gonzalez | Principal Accounting Officer & Senior VP of Finance | ||
Ms. Kimberley Hebert | Senior Director of Clinical Operations |
Adresse: United States, San Francisco, 100 Pine Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.adynxx.com
Nettsted: https://www.adynxx.com